Nautilus Biotechnology, Inc. Stock

Equities

NAUT

US63909J1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
2.4 USD -3.61% Intraday chart for Nautilus Biotechnology, Inc. -1.23% -19.73%
Sales 2024 * 204K Sales 2025 * 12.44M Capitalization 311M
Net income 2024 * -94M Net income 2025 * -114M EV / Sales 2024 * 959 x
Net cash position 2024 * 116M Net cash position 2025 * 61.42M EV / Sales 2025 * 20.1 x
P/E ratio 2024 *
-3.22 x
P/E ratio 2025 *
-2.73 x
Employees 167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.12%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Nautilus Biotechnology, Inc., Q3 2023 Earnings Call, Oct 31, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Nautilus Biotechnology, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:50 AM
Transcript : Nautilus Biotechnology, Inc., Q2 2023 Earnings Call, Aug 02, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Nautilus Biotechnology, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 04:40 PM
Transcript : Nautilus Biotechnology, Inc., Q1 2023 Earnings Call, May 02, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Nautilus Biotechnology, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nautilus Biotechnology Expands to San Diego CI
More news
1 day-3.61%
1 week-4.76%
Current month-18.37%
1 month-9.43%
3 months-21.31%
6 months+2.56%
Current year-19.73%
More quotes
1 week
2.31
Extreme 2.31
2.58
1 month
2.31
Extreme 2.31
3.09
Current year
2.31
Extreme 2.31
3.25
1 year
2.16
Extreme 2.16
4.65
3 years
1.50
Extreme 1.5
12.38
5 years
1.50
Extreme 1.5
25.89
10 years
1.50
Extreme 1.5
25.89
More quotes
Managers TitleAgeSince
Founder 47 15-12-31
Founder 49 15-12-31
Director of Finance/CFO 46 21-06-08
Members of the board TitleAgeSince
Chairman 56 18-12-31
Director/Board Member 62 21-06-08
Director/Board Member 59 21-06-08
More insiders
Date Price Change Volume
24-04-24 2.4 -3.61% 44,223
24-04-23 2.49 +2.89% 24,937
24-04-22 2.42 -1.63% 31,663
24-04-19 2.46 +5.13% 52,503
24-04-18 2.34 -3.70% 99,733

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.4 USD
Average target price
4.25 USD
Spread / Average Target
+77.08%
Consensus